| References | Intervention | OP treatment | (m/f) | Age (years) | FN BMD (g/cm2) | Fx prevalence (%) | BMSi | Relationship of BMSi with | Study quality scale (0–10) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | BMD | Intervention | |||||||||
| LONGITUDINAL DESIGN | |||||||||||
| Mellibovsky et al. (44) | GC and OP prophylaxis, FU 7 and 20 weeks (not shown) | Ca/Vit D | 19 (11/8) | 55.3 ± 17.9 | 0.83 ± 0.13 FU NA |
0.0 |
BL: 81.6 (74.3–86.9) FU: 71.9 (65.4–77.1) |
NA | NA | Decrease in Ca/Vit DIncrease in TPTD + Dmab | 7 |
| BP | 14 (10/4) | 66.1 ± 17.0 | 0.75 ± 0.14 FU NA |
7.1 |
BL: 81.1 (75.6–89.6) FU: 83.4 (76.6–93.0) |
||||||
| TPTD | 5 (1/4) | 69.8 ± 8.0 | 0.62 ± 0.12 FU NA |
60.0 |
BL: 70.0 (64.0–72.6) FU: 81.8 (73.3–88.9) |
||||||
| DMAb | 14 (5/9) | 58.9 ± 12.8 | 0.72 ± 0.15 FU NA |
14.3 |
BL: 76.2 (72.0–84.9) FU: 84.0 (79.2–90.0) |
||||||
| Tsai et al. (68) (Ab) | TPTD treatment, FU 3 months | TPTD 20 mg | 33 (0/33) | NA(52–83) | NA | NA |
BL: 82.1 ± 8.3* (61.5–102.7) FU: −4.8% |
NA | NA | Decrease in TPTD 20 + 40 mg | NA |
| TPTD 40 mg | 29 (0/29) |
BL: 83.2 ± 10.1* (67.1–99.3) FU: - 7.0% |
|||||||||
Age is presented as mean ± SD (range, if reported), BMD is presented as mean ± SD and BMSi is presented as mean ± SD (95% CI) or median (IQR). 95% CI calculated from data provided in the publication. Ab, published only in Abstract form; BL, Baseline; BMD, Bone mineral density; BMSi, Bone material strength index; BP, Bisphosphonate; Ca, Calcium; DMAb, Denosumab; FN, Femoral neck; FU, Follow-up; Fx, Fracture; GC, Glucocorticoid; OP, Osteoporosis; TPTD, Teriparatide. *Measured in a subgroup of subjects.